ASSET OVERVIEW
A closer look at the opportunity.
First-in-Class Inhibitor
Novel ENPP1 inhibitor that enhances cardiac repair post-MI through purinergic signaling modulation.
Strong Preclinical Efficacy
Significant improvements in EF, LVFS, and NT-proBNP in MI-induced heart failure models (rat/mouse).
High Selectivity & Safety
Clean safety profile in >250 pharmacology targets, no CNS/cardiovascular toxicities observed.
IND-Ready in 2024
IND submission Q4 2024, supported by robust preclinical pharmacology and GLP tox studies.
Cardiac Tissue Repair Mechanism
Differentiated approach vs. neurohormonal antagonists—targets cardiac fibrosis and scar remodeling.
Large Market Opportunity >$24.9B HF Market
Targets underserved post-MI HF population with high unmet need and poor survival outcomes.
Source: existing JEA asset materials. These descriptions include historical development plans and sponsor-reported data; contact JEA for current status and supporting materials.
← Back to all opportunities